biostudies-literatureUnknown11Konopasek P<h4>Aim</h4>The aim of this review is to provide clinicians with characteristics of children with nephrotic syndrome and cerebral sinovenous thrombosis (CSVT).<h4>Methods</h4>We have reviewed 37 articles of pediatric cases and provided 1 new case. PRISMA guidelines were followed.<h4>Results</h4>Sixty-two patients were included in the review. CSVT was more common in males, usually occurred within 6 months of nephrotic syndrome onset and was found more often in outpatients. The superior sagittal sinus was the most common sinus affected. Non-contrast computed tomography was the most frequent radiologic study performed, with 30% of results negative for CSVT. Headache and vomiting were the most common symptoms while neurologic symptoms were less frequent. Anticoagulation treatment was strongly Frontiers in pediatrics1207871https://www.ebi.ac.uk/biostudies/studies/S-EPMC10484110biostudies-literatureCerebral sinovenous thrombosis in children with nephrotic syndrome: systematic review and one new case.PMC10484110Zieg JKrejcova VKonopasek PPitekova BfalseCerebral sinovenous thrombosis in children with nephrotic syndrome: systematic review and one new case.<h4>Aim</h4>The aim of this review is to provide clinicians with characteristics of children with nephrotic syndrome and cerebral sinovenous thrombosis (CSVT).<h4>Methods</h4>We have reviewed 37 articles of pediatric cases and provided 1 new case. PRISMA guidelines were followed.<h4>Results</h4>Sixty-two patients were included in the review. CSVT was more common in males, usually occurred within 6 months of nephrotic syndrome onset and was found more often in outpatients. The superior sagittal sinus was the most common sinus affected. Non-contrast computed tomography was the most frequent radiologic study performed, with 30% of results negative for CSVT. Headache and vomiting were the most common symptoms while neurologic symptoms were less frequent. Anticoagulation treatment was strongly 2023-01-01T00:00:00Z20232025-04-04T19:36:38.52Z2025-04-04T19:36:38.52ZS-EPMC104841103769177210.3389/fped.2023.1207871